{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:23:03Z","timestamp":1787952183606,"version":"build-2784847793"},"reference-count":340,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.blre.2026.101391","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T14:50:57Z","timestamp":1776523857000},"page":"101391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure"],"prefix":"10.1016","volume":"77","author":[{"given":"B.","family":"Adhikari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2026.101391_bb0005","series-title":"Acute Myeloid Leukemia","author":"SEER Cancer Stat Facts","year":"2026"},{"key":"10.1016\/j.blre.2026.101391_bb0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V60.2.454.454","article-title":"Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study","volume":"60","author":"Yates","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0015","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.blre.2026.101391_bb0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2026.101391_bb0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.leukres.2015.06.017","article-title":"Bone marrow niche in the myelodysplastic syndromes","volume":"39","author":"Cogle","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101391_bb0030","doi-asserted-by":"crossref","first-page":"992","DOI":"10.18632\/oncotarget.27513","article-title":"Acute promyelocytic leukemia (APL): a review of the literature","volume":"11","author":"Jimenez","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101391_bb0035","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101391_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2011.12.009","article-title":"Monoclonal antibodies for the treatment of cancer","volume":"22","author":"Shuptrine","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.blre.2026.101391_bb0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2141.2009.08033.x","article-title":"Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells","volume":"148","author":"Stein","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101391_bb0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101391_bb0060","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1182\/blood.V94.11.3633","article-title":"Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47","volume":"94","author":"Seiffert","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0065","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-08-0554","article-title":"Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes","volume":"7","author":"Stahnke","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2026.101391_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2009.009811","article-title":"Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia","volume":"95","author":"Zhao","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0075","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V68.5.1030.1030","article-title":"The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors","volume":"68","author":"Andrews","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2362.2007.01746.x","article-title":"Expression of the target receptor CD33 in CD34+\/CD38-\/CD123+ AML stem cells","volume":"37","author":"Hauswirth","year":"2007","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.blre.2026.101391_bb0085","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0090","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","article-title":"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia","volume":"23","author":"Feldman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0095","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1080\/10428190903050013","article-title":"Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial","volume":"50","author":"Raza","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb0100","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0105","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.3324\/haematol.2022.281128","volume":"107","author":"Fiedler","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0110","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0115","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0120","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101391_bb0130","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V99.7.2310","article-title":"Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy","volume":"99","author":"Rajvanshi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0135","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0145","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0150","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2026.101391_bb0155","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0160","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0165","article-title":"Clinical benefits and safety of gemtuzumab ozogamicin in treating acute myeloid leukemia in various subgroups: an updated systematic review, meta-analysis, and network meta-analysis","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0170","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003471","article-title":"Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia","volume":"135","author":"Fournier","year":"2020","journal-title":"Blood"},{"issue":"346\u201352","key":"10.1016\/j.blre.2026.101391_bb0175","article-title":"A phase I\/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia","volume":"18","author":"Medeiros","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101391_bb0180","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/16078454.2022.2042964","article-title":"Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis","volume":"27","author":"Li","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2026.101391_bb0185","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bjh.19967","article-title":"CPX-351 +\/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study","volume":"206","author":"Ganzel","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101391_bb0190","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1182\/blood-2001-12-0174","article-title":"Experience with gemtuzumab ozogamycin (\u201cmylotarg\u201d) and all-trans retinoic acid in untreated acute promyelocytic leukemia","volume":"99","author":"Estey","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0195","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0200","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10637-011-9670-0","article-title":"Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed\/refractory acute myeloid leukemia","volume":"30","author":"Lapusan","year":"2012","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.blre.2026.101391_bb0205","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1182\/blood.V124.21.2321.2321","article-title":"The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutations","volume":"124","author":"Whiteman","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0210","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0215","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2018-03-841171","article-title":"A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML","volume":"132","author":"Fathi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0220","doi-asserted-by":"crossref","first-page":"TPS7066","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS7066","article-title":"Cascade: A phase 3, randomized, double-blind study on vadastuximab talirine versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"35","author":"Wang","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0225","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.V128.22.211.211","article-title":"A phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML)","volume":"128","author":"Erba","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0230","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V89.5.1471","article-title":"The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors","volume":"89","author":"Bagley","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0235","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41375-020-0773-5","article-title":"Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2\/3 study","volume":"35","author":"Montesinos","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0245","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/s41375-019-0645-z","article-title":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents","volume":"34","author":"Kubasch","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0250","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3109\/10428194.2014.956316","article-title":"A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia","volume":"56","author":"He","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb0255","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/protein\/13.8.575","article-title":"Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor","volume":"13","author":"Frankel","year":"2000","journal-title":"Protein Eng"},{"key":"10.1016\/j.blre.2026.101391_bb0260","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101391_bb0265","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood-2023-189417","article-title":"Single agent tagraxofusp in relapsed\/refractory CD123-positive Acute Myeloid Leukemia: A preliminary analysis of italian gimema AML2020 trial","volume":"142","author":"Minetto","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/bloodadvances.2023011721","article-title":"Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia","volume":"8","author":"Lane","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101391_bb0275","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S2152-2650(23)01027-3","article-title":"TAGALONG trial: phase II study of tagraxofusp and azacitidine with or without venetoclax in newly diagnosed secondary AML after previous exposure to hypomethylating agents","volume":"23","author":"Green","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101391_bb0280","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0285","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood-2025-651","article-title":"Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2026.101391_bb0290","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO-25-02083","article-title":"Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm","volume":"44","author":"Pemmaraju","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101391_bb0300","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0305","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000968912.12181.3e","article-title":"Isatuximab Plus Chemotherapy For Pediatric Relapsed\/Refractory Acute Lymphoblastic Leukemia Or Acute Myeloid Leukemia (ISAKIDS): interim efficacy analysis","volume":"7","author":"Baruchel","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.blre.2026.101391_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26136","article-title":"A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia","volume":"96","author":"Daver","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb0315","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4161\/cbt.25938","article-title":"Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia","volume":"14","author":"Guo","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.blre.2026.101391_bb0320","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ijc.2910440402","article-title":"Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma","volume":"44","author":"Patel","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0325","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.3576199","article-title":"Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing","volume":"236","author":"Cunningham","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101391_bb0330","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5581\/1516-8484.20110054","article-title":"The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia","volume":"33","author":"Alegretti","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"key":"10.1016\/j.blre.2026.101391_bb0335","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","article-title":"Characterization of a novel FLT3 BiTE molecule for the treatment of Acute Myeloid Leukemia","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2026.101391_bb0340","first-page":"2885","article-title":"High expression of FLT3 is a risk factor in leukemia","volume":"17","author":"Cheng","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.blre.2026.101391_bb0345","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V126.23.3806.3806","article-title":"AGS62P1, a novel anti-FLT3 antibody drug conjugate, employing site specific conjugation, demonstrates preclinical anti-tumor efficacy in AML tumor and patient derived xenografts","volume":"126","author":"Rudra-Ganguly","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0350","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.7059","article-title":"Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia","volume":"33","author":"Sanford","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0355","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-023-01490-w","article-title":"Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease","volume":"16","author":"Heitmann","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0360","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.12109","article-title":"Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML)","volume":"160","author":"Cerny","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101391_bb0365","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ejca.2009.02.021","article-title":"Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML","volume":"45","author":"Terwijn","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106385","article-title":"Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study","volume":"95","author":"Goldberg","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101391_bb0375","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/10428194.2012.728596","article-title":"CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis","volume":"54","author":"Fathi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb0380","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clml.2012.12.006","article-title":"CD30 expression in high-risk acute myeloid leukemia and myelodysplastic syndromes","volume":"13","author":"Zheng","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101391_bb0385","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0390","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0395","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cncr.32657","article-title":"A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed\/refractory acute myeloid leukemia","volume":"126","author":"Narayan","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0400","first-page":"1773","article-title":"Altered patterns of CD44 epitope expression in human chronic and acute myeloid leukemia","volume":"10","author":"Ghaffari","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0405","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1080\/10428194.2016.1263843","article-title":"Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed\/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia","volume":"58","author":"Vey","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb0410","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101391_bb0415","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101391_bb0420","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","article-title":"CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth","volume":"72","author":"Claus","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0425","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/mabs.27398","article-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","volume":"6","author":"Silence","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.blre.2026.101391_bb0430","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/PPO.0000000000000577","article-title":"Monoclonal antibodies in Acute Myeloid Leukemia-are we there yet?","volume":"28","author":"Abaza","year":"2022","journal-title":"Cancer J"},{"key":"10.1016\/j.blre.2026.101391_bb0435","first-page":"38","article-title":"CULMINATE: A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy","author":"Trudel","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0440","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3324\/haematol.2022.281563","article-title":"Results from a phase I\/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy","volume":"108","author":"Pabst","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0445","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1182\/blood-2021-150371","article-title":"Safety and Efficacy of Cusatuzumab in combination with Venetoclax and Azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; an open label, multicenter, phase 1b study","volume":"138","author":"Roboz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0450","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.V118.21.79.79","article-title":"Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study","volume":"118","author":"Delaunay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0455","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0460","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2021-145152","article-title":"Replacing the anthracycline by gemtuzumab ozogamicin in older patients with de novo standard-risk acute myeloid leukemia treated intensively - results of the randomized ALFA1401-mylofrance 4 study","volume":"138","author":"Lambert","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0465","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0470","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.2020.274118","article-title":"A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia","volume":"107","author":"Vasu","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0475","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41375-025-02528-3","article-title":"Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia","volume":"39","author":"Abedin","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0480","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1182\/blood-2023-178802","article-title":"Updated results from phase 1 study of targeted radiotherapy with lintuzumab-Ac225 in combination with venetoclax in relapsed\/refractory AML","volume":"142","author":"Roboz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0485","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.jmir.2019.03.113","article-title":"A phase 2 study of actinium-225 (225Ac)-lintuzumab in older patients with untreated Acute Myeloid Leukemia (AML)","volume":"50","author":"Atallah","year":"2019","journal-title":"J Med Imag Radiat Sci"},{"key":"10.1016\/j.blre.2026.101391_bb0490","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.215.215","article-title":"Results from ongoing phase 2 trial of SL-401 as consolidation therapy in patients with Acute Myeloid Leukemia (AML) in remission with high relapse risk including Minimal Residual Disease (MRD)","volume":"128","author":"Lane","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0495","doi-asserted-by":"crossref","first-page":"32532","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101391_bb0500","first-page":"13","article-title":"Immune therapies for myelodysplastic syndromes and acute myeloid leukemia","author":"Kapoor","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb0505","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fonc.2018.00152","article-title":"Therapeutic antibodies for myeloid neoplasms-current developments and future directions","volume":"8","author":"Schurch","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0510","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","article-title":"Radiation-induced cell death mechanisms","volume":"31","author":"Eriksson","year":"2010","journal-title":"Tumour Biol"},{"key":"10.1016\/j.blre.2026.101391_bb0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0145-2126(01)00096-0","article-title":"In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes","volume":"26","author":"Abbas Rizvi","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101391_bb0520","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","article-title":"Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting alpha-particles or Auger electrons","volume":"109","author":"Aghevlian","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.blre.2026.101391_bb0525","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V94.4.1237","article-title":"Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome","volume":"94","author":"Matthews","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0530","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1182\/blood-2014-12-617019","article-title":"Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment","volume":"127","author":"Orozco","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0535","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood-2005-06-2317","article-title":"131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission","volume":"107","author":"Pagel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0540","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0545","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2014.05.014","article-title":"Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome","volume":"20","author":"Mawad","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101391_bb0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1146\/annurev.immunol.21.120601.140946","article-title":"CD45: a critical regulator of signaling thresholds in immune cells","volume":"21","author":"Hermiston","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0555","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.23.02018","article-title":"Randomized phase III SIERRA trial of (131)I-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory AML","volume":"43","author":"Gyurkocza","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0560","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3324\/haematol.2019.229492","article-title":"Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed\/refractory leukemia or myelodysplasia","volume":"105","author":"Vo","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb0565","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/thno.21397","article-title":"Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics","volume":"8","author":"Habringer","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.blre.2026.101391_bb0570","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.V98.3.565","article-title":"Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study","volume":"98","author":"Bunjes","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0575","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1182\/blood-2010-06-284349","article-title":"Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases","volume":"117","author":"Schulz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0580","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood.V118.21.768.768","article-title":"Phase 1 trial of the targeted alpha-particle nano-generator actinium-225 (225Ac)-lintuzumab (anti-CD33;HuM195) in acute myeloid leukemia (AML)","volume":"118","author":"Jurcic","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0585","first-page":"2638","article-title":"A phase 2 study of actinium-225 (225Ac)-lintuzumab in older patients with previously untreated Acute Myeloid Leukemia (AML) unfit for intensive chemotherapy","volume":"130","author":"Finn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0590","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cam4.3665","article-title":"225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models","volume":"10","author":"Garg","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101391_bb0595","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17474086.2025.2449863","article-title":"Radioimmunotherapy of acute myeloid leukemia: a critical assessment of its prospects and limitations","volume":"18","author":"Bunjes","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb0600","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.blre.2026.101391_bb0605","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0610","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","article-title":"Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2026.101391_bb0615","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0620","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0625","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of Acute Myeloid Leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2026.101391_bb0630","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs\u2014Are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.blre.2026.101391_bb0635","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1182\/blood-2018-99-116264","article-title":"A next-generation Fc-bearing CD3-engaging bispecific DART\u00ae platform with extended pharmacokinetic and expanded pharmacologic window: characterization as CD123 x CD3 and CD19 x CD3 DART molecules","volume":"132","author":"Bonvini","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0640","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","article-title":"Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production","volume":"11","author":"Gleason","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.blre.2026.101391_bb0645","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 Trispecific Killer Engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0650","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0655","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0660","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary results from a phase 1 first-in-human study of AMG 673, a novel Half-Life Extended (HLE) anti-CD33\/CD3 BiTE\u00ae (bispecific T-cell engager) in patients with Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0665","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","article-title":"Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study","volume":"65","author":"Ravandi","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb0670","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-cell engager, in patients with Relapsed\/Refractory Acute Myeloid Leukemia (AML)","volume":"134","author":"Westervelt","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0675","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33 \u00d7 CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.blre.2026.101391_bb0690","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2024-208684","article-title":"Updated results from a phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-positive AML","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0695","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.3390\/cancers13164113","article-title":"A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome","volume":"13","author":"Uckun","year":"2021","journal-title":"Cancers"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101391_bb0700","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1182\/blood-2025-5198","volume":"146","author":"Justin Watts","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0780","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.blre.2026.101391_bb0715","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0680","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.V124.21.2316.2316","article-title":"Immunotherapy with long-lived anti-CD123 \u00d7 anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia","volume":"124","author":"Chu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0685","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101391_bb0705","doi-asserted-by":"crossref","first-page":"289ra82","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2026.101391_bb0710","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0720","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/cts.13467","article-title":"First-in-human study of JNJ-63709178, a CD123\/CD3 targeting antibody, in relapsed\/refractory acute myeloid leukemia","volume":"16","author":"Boyiadzis","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.blre.2026.101391_bb0725","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood.V126.23.325.325","article-title":"Preclinical evaluation of MCLA117, a CLEC12A x CD3 bispecific antibody efficiently targeting a novel leukemic stem cell associated antigen in AML","volume":"126","author":"Van Loo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0730","series-title":"Update From The Ongoing Phase I Multinational Study Of MCLA-117, A Bispecific CLEC12A X CD3 T-Cell Engager, In Patients with Acute Myelogenous Leukemia","author":"Mascarenhas","year":"2020"},{"key":"10.1016\/j.blre.2026.101391_bb0735","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0740","doi-asserted-by":"crossref","first-page":"1012841","DOI":"10.3389\/fimmu.2023.1012841","article-title":"Nanobodies in cell-mediated immunotherapy: On the road to fight cancer","volume":"14","author":"Maali","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0745","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Tapia-Galisteo","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.blre.2026.101391_bb0750","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.4143\/crt.2016.491","article-title":"Engineering of anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity","volume":"49","author":"Schmohl","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.blre.2026.101391_bb0755","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","article-title":"Novel human interleukin-15 agonists","volume":"183","author":"Zhu","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0760","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2026.101391_bb0765","series-title":"First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics","author":"Ashish Bajel","year":"2023"},{"key":"10.1016\/j.blre.2026.101391_bb0770","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb0775","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2018-05-849802","article-title":"Bifunctional PD-1 x alphaCD3 x alphaCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia","volume":"132","author":"Herrmann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0785","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.blre.2026.101391_bb0790","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101391_bb0795","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0800","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0805","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.blre.2026.101391_bb0810","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.celrep.2016.10.042","article-title":"Programmed death-1 culls peripheral accumulation of high-affinity autoreactive CD4 T cells to protect against autoimmunity","volume":"17","author":"Jiang","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.blre.2026.101391_bb0815","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0820","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (pembro) and Azacitidine (AZA) in patients with relapsed\/refractory Acute Myeloid Leukemia (AML) and in newly diagnosed (\u226565 Years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0825","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.blre.2026.101391_bb0830","article-title":"Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia. transplantation and cellular","volume":"27","author":"Tschernia","year":"2021","journal-title":"Therapy"},{"key":"10.1016\/j.blre.2026.101391_bb0835","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7026","article-title":"Phase IB\/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML","volume":"35","author":"Daver","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0840","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2018-99-116078","article-title":"Results of a phase 2, open-label study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)","volume":"132","author":"Assi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0845","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7014","article-title":"Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients","volume":"36","author":"Kadia","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0850","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101391_bb0855","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2022.2062345","article-title":"A multi-arm phase Ib\/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed\/refractory acute myeloid leukemia","volume":"63","author":"Short","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb0860","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/cncr.33690","article-title":"A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia","volume":"127","author":"Saxena","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb0865","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41590-023-01571-5","article-title":"CTLA-4 tail fusion enhances CAR-T antitumor immunity","volume":"24","author":"Zhou","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0870","doi-asserted-by":"crossref","first-page":"1198365","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0875","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","article-title":"Expression patterns of immune checkpoints in acute myeloid leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0880","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood.2022017686","article-title":"Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings","volume":"141","author":"Garcia","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0885","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101391_bb0890","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2024-211343","article-title":"A phase I study of nivolumab in combination with ipilimumab for the treatment of patients with high risk or refractory\/relapsed acute myeloid leukemia following allogeneic stem cell transplantation","volume":"144","author":"Alatrash","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0895","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-024-06081-4","article-title":"A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome","volume":"104","author":"Garcia-Manero","year":"2025","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb0900","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.blre.2026.101391_bb0905","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1084\/jem.20100687","article-title":"Tim3 binding to galectin-9 stimulates antimicrobial immunity","volume":"207","author":"Jayaraman","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2026.101391_bb0910","article-title":"One stone, Two birds: the roles of Tim-3 in Acute Myeloid Leukemia","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0915","doi-asserted-by":"crossref","first-page":"8956","DOI":"10.1002\/cam4.5549","article-title":"Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101391_bb0920","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S2152-2650(22)01303-9","article-title":"AML-484 first results of a phase II study (STIMULUS-AML1) investigating sabatolimab + azacitidine + venetoclax in patients with Newly Diagnosed Acute Myeloid Leukemia (ND AML)","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101391_bb0925","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2023-180876","article-title":"TIM-3 inhibitor sabatolimab for patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): preliminary findings from the phase Ib\/II Stimulus-AML2 study","volume":"142","author":"Zeiser","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0930","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2026.101391_bb0935","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb0940","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb0945","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101391_bb0950","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2026.101391_bb0955","series-title":"The First-in-class Anti-CD47 Antibody Magrolimab Combined with Azacitidine is Well-tolerated and Effective in MDS Patients: Phase 1B Results","author":"Sallman","year":"2020"},{"key":"10.1016\/j.blre.2026.101391_bb0960","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0965","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-25-0229","article-title":"Azacitidine, venetoclax, and magrolimab in newly diagnosed and relapsed refractory acute myeloid leukemia: phase Ib\/II study and correlative analysis","volume":"31","author":"Daver","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb0970","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0975","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/trf.15397","article-title":"The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia","volume":"59","author":"Brierley","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2026.101391_bb0980","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb0985","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb0990","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb0995","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/jcm13041082","article-title":"Unmet horizons: assessing the challenges in the treatment of TP53-mutated Acute Myeloid Leukemia","volume":"13","author":"Stafylidis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2026.101391_bb1000","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-134391","article-title":"A phase I\/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): initial phase I results","volume":"136","author":"Qi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1182\/blood.2024027222","article-title":"Targeting CD47: many misses; hopeful for a hit","volume":"145","author":"Wilde","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1010","doi-asserted-by":"crossref","first-page":"1349081","DOI":"10.3389\/fphar.2023.1349081","article-title":"Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy","volume":"14","author":"Su","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2026.101391_bb1015","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2024-206538","article-title":"IO-202, a novel anti-LILRB4 antibody, with azacitidine for hypomethylating agent-naive chronic myelomonocytic leukemia: phase 1b expansion cohort results","volume":"144","author":"Mannis","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1020","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/biomedicines11061724","article-title":"Checkpoint inhibitors in acute myeloid leukemia","volume":"11","author":"Damiani","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2026.101391_bb1025","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101391_bb1030","doi-asserted-by":"crossref","first-page":"7785","DOI":"10.4049\/jimmunol.180.12.7785","article-title":"Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity","volume":"180","author":"Strowig","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/iji.12387","article-title":"Current strategies exploiting NK-cell therapy to treat haematologic malignancies","volume":"45","author":"Johnson","year":"2018","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.blre.2026.101391_bb1040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fimmu.2016.00094","article-title":"Underground adaptation to a hostile environment: acute myeloid leukemia vs. natural killer cells","volume":"7","author":"Dulphy","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1045","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1182\/blood-2006-07-035519","article-title":"Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors","volume":"109","author":"Epling-Burnette","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41375-023-01849-5","article-title":"The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial","volume":"37","author":"Lee","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1060","doi-asserted-by":"crossref","DOI":"10.1177\/09636897231198178","article-title":"Haploidentical natural killer cell therapy as an adjunct to stem cell transplantation for treatment of refractory acute myeloid leukemia","volume":"32","author":"Kulkarni","year":"2023","journal-title":"Cell Transplant"},{"key":"10.1016\/j.blre.2026.101391_bb1065","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/trf.16790","article-title":"Clinical grade production of IL-15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide","volume":"62","author":"Rubio-Azpeitia","year":"2022","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2026.101391_bb1070","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1075","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2026.101391_bb1080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41375-021-01349-4","article-title":"Decrease post-transplant relapse using donor-derived expanded NK-cells","volume":"36","author":"Ciurea","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2026.101391_bb1090","first-page":"13","article-title":"Phase I trial of prophylactic donor-derived IL-2-activated NK cell infusion after allogeneic hematopoietic stem cell transplantation from a matched sibling donor","author":"Devillier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb1095","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"Jaiswal","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2026.101391_bb1100","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101391_bb1105","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.bbmt.2016.04.009","article-title":"Haploidentical natural killer cells infused before allogeneic stem cell transplantation for myeloid malignancies: a phase I trial","volume":"22","author":"Lee","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101391_bb1110","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1182\/blood.V128.22.1161.1161","article-title":"Prophylactic natural killer cell immunotherapy following HLA-haploidentical hematopoietic cell transplantation prevents relapse and improves survival in patients with high-risk hematological malignancies","volume":"128","author":"Thakar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1115","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.27281","article-title":"Results of a phase I trial with haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML","volume":"99","author":"Ciurea","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb1120","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","article-title":"Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients","volume":"23","author":"Ahmadvand","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb1125","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.2021011532","article-title":"Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy","volume":"139","author":"Berrien-Elliott","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1130","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1182\/blood-2022-170712","article-title":"Off-the-shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human, phase I trial","volume":"140","author":"Huang","year":"2022","journal-title":"Blood"},{"issue":"328\u201337","key":"10.1016\/j.blre.2026.101391_bb1135","article-title":"Phase 2 clinical trial of infusing haploidentical K562-mb15-41BBL-activated and expanded natural killer cells as consolidation therapy for pediatric acute myeloblastic leukemia","volume":"21","author":"Gomez Garcia","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2026.101391_bb1140","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood-2021-150750","article-title":"A phase I clinical trial testing the safety of IL-21-expanded, universally alloreactive donor-derived natural killer cells for relapsed\/refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome","volume":"138","author":"Vasu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1145","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.17751","article-title":"Adoptive immunotherapy with double-bright (CD56(bright) \/CD16(bright)) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study","volume":"195","author":"Silla","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101391_bb1150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10428194.2024.2414903","article-title":"MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study","volume":"66","author":"Kim","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2026.101391_bb1155","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2026.101391_bb1160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jcyt.2020.02.001","article-title":"Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia","volume":"22","author":"Mani","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2026.101391_bb1165","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/eji.201948375","article-title":"Expanded clinical-grade membrane-bound IL-21\/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo","volume":"50","author":"Zhao","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1170","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101391_bb1175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","article-title":"A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia","volume":"7","author":"Nguyen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb1180","first-page":"812","article-title":"Observation on the efficacy of consolidation chemotherapy combined with allogeneic natural killer cell infusion in the treatment of low and moderate risk acute myeloid leukemia","volume":"40","author":"Wang","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.blre.2026.101391_bb1185","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2018.03.019","article-title":"A phase 1 trial of CNDO-109-activated natural killer cells in patients with high-risk acute myeloid leukemia","volume":"24","author":"Fehniger","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101391_bb1190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2018.02.033","article-title":"Haploidentical IL-15\/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia","volume":"422","author":"Vela","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.blre.2026.101391_bb1200","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful transfer of Umbilical Cord Blood CD34(+) hematopoietic stem and progenitor-derived NK cells in older Acute Myeloid Leukemia patients","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb1205","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1158\/1078-0432.CCR-15-1604","article-title":"Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly Acute Myeloid Leukemia patients","volume":"22","author":"Curti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb1210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood.V126.23.566.566","article-title":"A phase I study of intravenous NCI IL-15 to enhance adoptively transferred NK cells uncovers defects in CD16 triggered IFN\u03b3 production and competition between donor NK and recipient T cells","volume":"126","author":"Miller","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1215","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1007\/s00262-022-03217-1","article-title":"Natural killer cells and acute myeloid leukemia: promises and challenges","volume":"71","author":"Rahmani","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2026.101391_bb1220","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb1225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","article-title":"The rise of allogeneic natural killer cells as a platform for cancer immunotherapy: recent innovations and future developments","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1230","first-page":"12","article-title":"Natural born killers: NK cells in cancer therapy","author":"Franks","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb1235","first-page":"11","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","author":"Lupo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb1240","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/curroncol28020105","article-title":"The advances and challenges of NK cell-based cancer immunotherapy","volume":"28","author":"Kang","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1245","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.blre.2026.101391_bb1250","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.blre.2026.101391_bb1255","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","article-title":"Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation","volume":"102","author":"Rezvani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1260","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","article-title":"Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53","volume":"52","author":"Rajabi","year":"2025","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.blre.2026.101391_bb1265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.blre.2026.101391_bb1270","first-page":"14","article-title":"Vaccination therapy for acute myeloid leukemia: Where do we stand?","author":"Barbullushi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb1275","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101391_bb1280","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","article-title":"RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses","volume":"111","author":"Schmitt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1285","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","article-title":"The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies","volume":"25","author":"Soleimani Samarkhazan","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.blre.2026.101391_bb1290","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00262-016-1938-y","article-title":"Targeting of the WT1(91-138) fragment to human dendritic cells improves leukemia-specific T-cell responses providing an alternative approach to WT1-based vaccination","volume":"66","author":"Dagvadorj","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.blre.2026.101391_bb1295","article-title":"A peptide vaccine design targeting KIT mutations in Acute Myeloid Leukemia","volume":"16","author":"Kim","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb1300","article-title":"Interim analysis of phase 3 REGAL trial of GPS in Acute Myeloid Leukemia. January 23,2025: SELLAS","author":"Sciences","year":"2025","journal-title":"Life Sci"},{"key":"10.1016\/j.blre.2026.101391_bb1305","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajh.24014","article-title":"WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides","volume":"90","author":"Brayer","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb1310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","article-title":"Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia","volume":"116","author":"Maslak","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1315","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1320","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101391_bb1325","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1330","first-page":"9","article-title":"Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb1335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1340","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.blre.2026.101391_bb1345","first-page":"12","article-title":"Dendritic cells as a therapeutic strategy in Acute Myeloid Leukemia: vaccines","author":"Palomares","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.blre.2026.101391_bb1350","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1080\/21645515.2021.1943991","article-title":"A phase I\/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients","volume":"17","author":"Chevallier","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.blre.2026.101391_bb1355","doi-asserted-by":"crossref","first-page":"1151032","DOI":"10.3389\/fphar.2023.1151032","article-title":"A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.blre.2026.101391_bb1360","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1365","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14653240902960411","article-title":"Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial","volume":"11","author":"Van Driessche","year":"2009","journal-title":"Cytotherapy"},{"key":"10.1016\/j.blre.2026.101391_bb1370","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1117","article-title":"Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial","volume":"9","author":"Lichtenegger","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1375","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.bbmt.2016.08.028","article-title":"Induction of immune response after allogeneic Wilms\u2019 tumor 1 dendritic cell vaccination and donor lymphocyte infusion in patients with hematologic malignancies and post-transplantation relapse","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2026.101391_bb1380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01523-4","article-title":"Vaccines: a promising therapy for myelodysplastic syndrome","volume":"17","author":"Gera","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1385","series-title":"Wilms\u2019 Tumor 1(WT1) RNA-Electroporated Dendritic Cell Vaccination as Post-remission Treatment to Prevent or Delay Relapse in Acute Myeloid Leukemia: Final Results of a Phase II Study in 30 patients","author":"Berneman","year":"2017"},{"key":"10.1016\/j.blre.2026.101391_bb1390","series-title":"Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I\/II Trial in AML patients","author":"M","year":"2020"},{"key":"10.1016\/j.blre.2026.101391_bb1395","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1200\/jco.2015.33.15_suppl.7007","article-title":"Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine","volume":"33","author":"Khoury","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1400","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2026.101391_bb1405","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood-2024-201374","article-title":"Active immunotherapy with vididencel as maintenance treatment in MRD+ AML patients in CR1 results in strong anti-tumor immune responses and durable long-term survival in patients with an immune competent immune profile","volume":"144","author":"van de Loosdrecht","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1410","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12032-025-02787-1","article-title":"Targeting platelet-tumor cell interactions: a novel approach to cancer therapy","volume":"42","author":"Rab","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1415","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","article-title":"Immune checkpoint inhibitors in Acute Myeloid Leukemia: novel combinations and therapeutic targets","volume":"21","author":"Stahl","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.blre.2026.101391_bb1420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12094-019-02132-9","article-title":"Immunomodulation in leukemia: cellular aspects of anti-leukemic properties","volume":"22","author":"Maleknia","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1425","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1430","doi-asserted-by":"crossref","DOI":"10.1177\/20406207251326802","article-title":"Recent advances of CAR-T cells in acute myeloid leukemia","volume":"16","author":"Deng","year":"2025","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2026.101391_bb1435","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2026.101391_bb1440","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of Chimeric Antigen Receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2026.101391_bb1445","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","article-title":"The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways","volume":"64","author":"Irving","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101391_bb1450","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2002-04-1041","article-title":"Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors","volume":"100","author":"Haynes","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1455","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1460","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.blre.2026.101391_bb1465","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2026.101391_bb1470","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101391_bb1475","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2026.101391_bb1480","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152457","article-title":"Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis","volume":"14","author":"Shahzad","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1485","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2026.101391_bb1490","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1016\/j.blre.2026.101391_bb1495","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1500","article-title":"CD33 CAR T-Cells (CD33CART) for children and young adults with Relapsed\/Refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1505","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.blre.2026.101391_bb1510","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1515","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12026-007-0060-9","article-title":"The NKG2D receptor: immunobiology and clinical implications","volume":"40","author":"Burgess","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.blre.2026.101391_bb1520","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"10.1016\/j.blre.2026.101391_bb1525","first-page":"7","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.blre.2026.101391_bb1530","first-page":"10","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101391_bb1535","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1038\/s41375-025-02767-4","article-title":"Downregulation of MICA\/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia","volume":"39","author":"Pollyea","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1540","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1182\/blood.V126.23.3778.3778","article-title":"First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia","volume":"126","author":"Luo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1545","first-page":"1359","article-title":"Treating Relapsed \/ Refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1550","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1555","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: A first-in-human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1560","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1565","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2023-177867","article-title":"Updated results from a phase I dose escalation study of the rapidly-switchable universal CAR-T therapy UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"142","author":"Wermke","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1570","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2023-180387","article-title":"A phase I clinical trial of CLL-1 CAR-T cells for the treatment of Relapsed\/Refractory Acute Myeloid Leukemia in adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1575","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1491341","article-title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1580","first-page":"615","article-title":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb1585","series-title":"Presented at: 25th European Hematology Association Congress Virtual; June 11-21, 2020. Abstract S149. 25th European Hematology Association Congress","article-title":"First-in-human CLL1-CD33 compound CAR (CCAR) T cell therapy in Relapsed and Refractory Acute Myeloid Leukemia","author":"Liu","year":"2020"},{"key":"10.1016\/j.blre.2026.101391_bb1590","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1595","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1073\/pnas.88.2.603","article-title":"Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine Thy-1 gene","volume":"88","author":"Schanberg","year":"1991","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.blre.2026.101391_bb1600","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1385\/IR:24:1:31","article-title":"T cell signal transduction and the role of CD7 in costimulation","volume":"24","author":"Stillwell","year":"2001","journal-title":"Immunol Res"},{"key":"10.1016\/j.blre.2026.101391_bb1605","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.leukres.2006.06.001","article-title":"CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype","volume":"31","author":"Chang","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2026.101391_bb1610","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1615","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101391_bb1620","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1625","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1186\/s12967-025-07151-5","article-title":"CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.blre.2026.101391_bb1630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coche.2017.11.006","article-title":"CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy","volume":"19","author":"Rosenberg","year":"2018","journal-title":"Curr Opin Chem Eng"},{"key":"10.1016\/j.blre.2026.101391_bb1635","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/bjh.17186","article-title":"Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity","volume":"193","author":"Rafei","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2026.101391_bb1640","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.blre.2026.101391_bb1645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1650","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-173582","article-title":"A phase 1 study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with Acute Myeloid Leukemia","volume":"142","author":"Sauter","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1655","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1660","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/cam4.5916","article-title":"Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2026.101391_bb1665","first-page":"12","article-title":"Antigen-specific TCR-T cells for Acute Myeloid Leukemia: state of the art and challenges","author":"Kang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2026.101391_bb1670","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.blre.2026.101391_bb1675","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.blre.2026.101391_bb1680","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41375-023-01976-z","article-title":"Who wins the combat, CAR or TCR?","volume":"37","author":"Yun","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2026.101391_bb1685","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","article-title":"Current developments in T-cell receptor therapy for acute myeloid leukemia","volume":"9","author":"Gore","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2026.101391_bb1690","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2015.141796","article-title":"Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia","volume":"101","author":"Rampal","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2026.101391_bb1695","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene\u2212transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1700","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2026.101391_bb1705","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood.2024024105","article-title":"HA-1\u2013targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation","volume":"144","author":"Krakow","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101391_bb1710","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study","volume":"11","author":"van Balen","year":"2020","journal-title":"Front Immunol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:11:34Z","timestamp":1787951494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":340,"alternative-id":["S0268960X26000305"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101391","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101391"}}